Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 ...

Nuvation Bio (NUVB) announced enrollment of the first patient into part 2 of G203, a global, randomized study evaluating the efficacy and safety ...

Tiragolumab plus atezolizumab does not improve survival compared to durvalumab in locally advanced, unresectable, stage 3 NSCLC.

Guardant Health's accepted abstracts span multiple tumor types, including lung, colorectal, breast, head and neck, and cancers of unknown primary. Together, they underscore the company's commitment to ...

Investigators have developed a prognostic model that may identify which patients with MIBC are suitable for bladder-preserving chemoradiation.

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective ...

Previously, the primary endpoint results of the NRG-LU005 study assessing the addition of the immunotherapy drug atezolizumab to standard of care concurrent chemoradiation for limited-state small cell ...

PARIS and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based ...

Currently, effective preventive therapies beyond statins for radiation therapy (RT)‐induced cardiovascular disease are unknown. A history of neck RT is associated with a 7‐fold increased odds ratio ...

Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immuno-oncology. ICIs act on cancer cells by blocking the interaction between immune checkpoint proteins on immune cells and ...